- Home
- CREV vs ONCO Comparison
CREV vs ONCO Comparison
Compare CREV & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CREV | ONCO |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | CREV | ONCO |
|---|---|---|
| Price | $1.66 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.2K | 31.4K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,677,475.00 | $1,223,751.00 |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $1.48 | $2.10 |
| 52 Week High | $12.75 | $179.35 |
Technical Indicators
Market Signals| Indicator | CREV | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 44.50 |
| Support Level | $1.64 | $2.53 |
| Resistance Level | $2.85 | $3.22 |
| Average True Range (ATR) | 0.24 | 0.30 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 17.20 | 32.72 |
Price Performance
Historical ComparisonAbout CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.